{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:18:02Z","timestamp":1791389882834,"version":"4.3.3"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473290"],"award-info":[{"award-number":["82473290"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ctrv.2026.103091","type":"journal-article","created":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T07:03:46Z","timestamp":1768115026000},"page":"103091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody\u2013Drug conjugates"],"prefix":"10.1016","volume":"143","author":[{"given":"Yuwei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103091_b0005","article-title":"Small-cell lung cancer","volume":"7(1):3","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers Jan 14"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103091_b0010","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrc.2017.87","article-title":"Small-cell lung cancer: what we know, what we need to know and the path forward","volume":"17","author":"Gazdar","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103091_b0015","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/S1470-2045(18)30455-8","article-title":"Will liquid biopsies improve outcomes for patients with small-cell lung cancer?","volume":"19","author":"Blackhall","year":"2018","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103091_b0020","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.3390\/curroncol29120709","article-title":"Chemo-Immunotherapy in first Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): a Systematic Review and Meta-Analysis","volume":"29","author":"Sathiyapalan","year":"2022","journal-title":"Curr Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103091_b0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0030","doi-asserted-by":"crossref","unstructured":"Li S, Lv J, Li Z, et al. Overcoming multi-drug resistance in SCLC: a synergistic approach with venetoclax and hydroxychloroquine targeting the lncRNA LYPLAL1-DT\/BCL2\/BECN1 pathway. Mol Cancer. Oct 31 2024;23(1):243. doi:10.1186\/s12943-024-02145-1.","DOI":"10.1186\/s12943-024-02145-1"},{"key":"10.1016\/j.ctrv.2026.103091_b0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.pharmthera.2017.06.002","article-title":"Treatment advances in small cell lung cancer (SCLC)","volume":"180","author":"Waqar","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2026.103091_b0040","article-title":"Neuroendocrine features in small cell lung cancer (SCLC) and associations with platinum-sensitivity, metastatic tropism, and overall survival","volume":"42(16_suppl):e20113\u2013e20113","author":"He","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103091_b0045","first-page":"620","article-title":"Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin Nov-Dec"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103091_b0050","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of First-Line Serplulimab vs Placebo added to Chemotherapy on Survival in patients with Extensive-Stage Small Cell Lung Cancer: the ASTRUM-005 Randomized Clinical Trial","volume":"328","author":"Cheng","year":"2022","journal-title":"J Am Med Assoc"},{"issue":"10212","key":"10.1016\/j.ctrv.2026.103091_b0055","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ctrv.2026.103091_b0060","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1200\/JCO.2006.08.3998","article-title":"Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer","volume":"25","author":"Eckardt","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0065","doi-asserted-by":"crossref","unstructured":"Cheng Y, Wu C, Wu L, et al. A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancer. Sci Rep. Feb 13 2024;14(1):3598. doi:10.1038\/s41598-024-54223-5.","DOI":"10.1038\/s41598-024-54223-5"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103091_b0070","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously Treated Small-Cell Lung Cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103091_b0075","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","article-title":"The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development","volume":"14","author":"Colombo","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2026.103091_b0080","doi-asserted-by":"crossref","unstructured":"Meng Y, Wang X, Yang J, et al. Antibody-drug conjugates treatment of small cell lung cancer: advances in clinical research. Discov Oncol. Aug 1 2024;15(1):327. doi:10.1007\/s12672-024-01171-1.","DOI":"10.1007\/s12672-024-01171-1"},{"key":"10.1016\/j.ctrv.2026.103091_b0085","article-title":"ZL-1310, a DLL3 ADC, in patients with extensive stage small cell lung cancer: Ph1 trial update","volume":"43(16_suppl):3041\u20133041","author":"Patel","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0090","doi-asserted-by":"crossref","unstructured":"Wang J, Wu L, Li X, et al. OA04.05 SHR-A1921, A TROP-2 Targeted Antibody-Drug Conjugate (ADC), In Patients (pts) with Advanced Small-Cell Lung Cancer (SCLC). Journal of Thoracic Oncology. 2024\/10\/01\/ 2024;19(10, Supplement):S16-S17. Doi: 10.1016\/j.jtho.2024.09.035.","DOI":"10.1016\/j.jtho.2024.09.035"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103091_b0095","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103091_b0100","article-title":"Assessment of targets of antibody drug conjugates in SCLC","volume":"9(1):1","author":"Ajay","year":"2025","journal-title":"NPJ Precis Oncol Jan 2"},{"key":"10.1016\/j.ctrv.2026.103091_b0105","doi-asserted-by":"crossref","unstructured":"Huang D, Wang J, Chen L, et al. Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future Perspectives. Molecules. Apr 12 2025;30(8)doi:10.3390\/molecules30081731.","DOI":"10.3390\/molecules30081731"},{"key":"10.1016\/j.ctrv.2026.103091_b0110","doi-asserted-by":"crossref","unstructured":"Owonikoko TK, Elliott A, Dwivedi B, et al. Surfaceome profiling to reveal unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC). Journal of Clinical Oncology. 2022\/06\/01 40(16_suppl):8515-8515. doi:10.1200\/JCO.2022.40.16_suppl.8515.","DOI":"10.1200\/JCO.2022.40.16_suppl.8515"},{"key":"10.1016\/j.ctrv.2026.103091_b0115","article-title":"Clinical Pharmacology of Antibody-Drug Conjugates. Antibodies (Basel)","volume":"10(2)doi:10.3390\/antib10020020","author":"Mahmood","year":"2021","journal-title":"May 21"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103091_b0120","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s12325-017-0519-6","article-title":"Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: a Review","volume":"34","author":"Lambert","year":"2017","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103091_b0125","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.neo.2020.12.001","article-title":"Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping","volume":"23","author":"Khera","year":"2021","journal-title":"Neoplasia"},{"issue":"15","key":"10.1016\/j.ctrv.2026.103091_b0130","doi-asserted-by":"crossref","first-page":"10540","DOI":"10.1074\/jbc.M510026200","article-title":"Lysosomal trafficking and Cysteine Protease Metabolism Confer Target-specific Cytotoxicity by Peptide-linked Anti-CD30-Auristatin Conjugates*","volume":"281","author":"Sutherland","year":"2006","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103091_b0135","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody\u2013drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103091_b0140","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0145","doi-asserted-by":"crossref","unstructured":"Chis AA, Dobrea CM, Arseniu AM, et al. Antibody-Drug Conjugates-Evolution and Perspectives. Int J Mol Sci. Jun 26 2024;25(13)doi:10.3390\/ijms25136969.","DOI":"10.3390\/ijms25136969"},{"key":"10.1016\/j.ctrv.2026.103091_b0150","doi-asserted-by":"crossref","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Signal Transduct Target Ther. Mar 22 2022;7(1):93. doi:10.1038\/s41392-022-00947-7.","DOI":"10.1038\/s41392-022-00947-7"},{"key":"10.1016\/j.ctrv.2026.103091_b0155","unstructured":"Zuo S. Measuring Drug-to-Antibody Ratio (DAR) for Antibody-Drug Conjugates (ADCs) with UHPLC \/ Q-TOF Application Note. 2016."},{"key":"10.1016\/j.ctrv.2026.103091_b0160","doi-asserted-by":"crossref","unstructured":"Tang Y, Tang F, Yang Y, et al. Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality Control. Sci Rep. Aug 10 2017;7(1):7763. doi:10.1038\/s41598-017-08151-2.","DOI":"10.1038\/s41598-017-08151-2"},{"key":"10.1016\/j.ctrv.2026.103091_b0165","doi-asserted-by":"crossref","unstructured":"de Brito RV, Mancini MW, Palumbo MDN, et al. The Rationale for \u201cLaser-Induced Thermal Therapy (LITT) and Intratumoral Cisplatin\u201d Approach for Cancer Treatment. Int J Mol Sci. May 25 2022;23(11)doi:10.3390\/ijms23115934.","DOI":"10.3390\/ijms23115934"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103091_b0170","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.3390\/molecules28083356","article-title":"Targeting B7-H3\u2014A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid Tumors Treatment","volume":"28","author":"Rasic","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ctrv.2026.103091_b0175","article-title":"Targeting Trop-2 in solid tumors: future prospects","volume":"12(null):1781\u20131790","author":"Zaman","year":"2019","journal-title":"OncoTargets and Therapy"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103091_b0180","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/oncolo\/oyac161","article-title":"DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms","volume":"27","author":"Yao","year":"2022","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103091_b0185","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1535-7163.MCT-21-0851","article-title":"ABBV-011, a Novel, Calicheamicin-based Antibody-Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors","volume":"21","author":"Wiedemeyer","year":"2022","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103091_b0190","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cllc.2016.09.002","article-title":"Phase 1\/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination with Carboplatin\/Etoposide in Small-Cell Lung Cancer patients with Extensive-Stage Disease","volume":"18","author":"Socinski","year":"2017","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103091_b0195","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103091_b0200","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.yexcr.2012.09.006","article-title":"Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response","volume":"319","author":"Chen","year":"2013","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.ctrv.2026.103091_b0205","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.600238","article-title":"The Expression of three negative Co-Stimulatory B7 Family Molecules in Small Cell Lung Cancer and their effect on Prognosis","volume":"11","author":"Qiu","year":"2021","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103091_b0210","first-page":"2646","article-title":"B7-H3 expression associates with tumor invasion and patient's poor survival in human esophageal cancer","volume":"7","author":"Chen","year":"2015","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ctrv.2026.103091_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101801","article-title":"B7-H3\/CD276 and small-cell lung cancer: What's new?","volume":"39","author":"Fabrizio","year":"2024","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0220","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/ITT.S507522","article-title":"Tumor Immunotherapy Targeting B7-H3: from Mechanisms to Clinical applications","volume":"14","author":"Guo","year":"2025","journal-title":"ImmunoTargets Ther"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103091_b0225","doi-asserted-by":"crossref","first-page":"816","DOI":"10.7150\/jca.17759","article-title":"B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K\/Akt\/STAT3 Signaling Pathway","volume":"8","author":"Li","year":"2017","journal-title":"J Cancer"},{"key":"10.1016\/j.ctrv.2026.103091_b0230","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8824805","article-title":"B7-H3-Induced Signaling in Lung Adenocarcinoma Cell Lines with Divergent Epidermal Growth factor Receptor Mutation patterns","volume":"2020","author":"Ding","year":"2020","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ctrv.2026.103091_b0235","doi-asserted-by":"crossref","first-page":"S744","DOI":"10.1016\/j.annonc.2022.07.582","article-title":"453O DS-7300 (B7-H3 DXd antibody-drug conjugate [ADC]) shows durable antitumor activity in advanced solid tumors: Extended follow-up of a phase I\/II study","volume":"33","author":"Doi","year":"2022","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103091_b0240","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.jtho.2023.09.042","article-title":"OA05.05 Ifinatamab Deruxtecan (I-DXd; DS-7300) in patients with Refractory SCLC: a Subgroup Analysis of a phase 1\/2 Study","volume":"18","author":"Johnson","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0245","doi-asserted-by":"crossref","unstructured":"Rudin CM, Johnson ML, Paz-Ares L, et al. Ifinatamab Deruxtecan in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase II IDeate-Lung01 Trial. J Clin Oncol. Oct 14 2025:Jco2502142. doi:10.1200\/jco-25-02142.","DOI":"10.1200\/JCO-25-02142"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103091_b0250","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103091_b0255","doi-asserted-by":"crossref","unstructured":"Wang J, Duan J, Wu L, et al. OA04.06 Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in A Multicenter, Phase 1 Study (ARTEMIS-001). Journal of Thoracic Oncology. 2024\/10\/01\/ 2024;19(10, Supplement):S17. Doi: 10.1016\/j.jtho.2024.09.036.","DOI":"10.1016\/j.jtho.2024.09.036"},{"key":"10.1016\/j.ctrv.2026.103091_b0260","article-title":"OA04.06 Efficacy and Safety of HS-20093 in Extensive Stage Small Cell Lung Cancer in a Multicenter, phase 1 Study (ARTEMIS-001)","volume":"19(10):S17","author":"Wang","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0265","article-title":"OA06.02 Safety and Efficacy of QLC5508 in previously Treated patients with Small Cell Lung Cancer: Updated Data from a phase 1 Study","volume":"20(10, Supplement 1):S21\u2013S22","author":"Zhou","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0270","article-title":"Results from a phase 1\/2 study of 7MW3711: a novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with lung cancer","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0275","article-title":"Results from a phase 1\/2 study of 7MW3711: a novel B7-H3 antibody-drug conjugate (ADC) incorporating a topoisomerase I inhibitor in patients with lung cancer","volume":"43(16_suppl):3036\u20133036","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0280","doi-asserted-by":"crossref","first-page":"S1426","DOI":"10.1016\/j.annonc.2024.10.078","article-title":"57O a phase I\/II multicenter, first-in-human study of DB-1311\/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors","volume":"35","author":"Cheng","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0285","doi-asserted-by":"crossref","unstructured":"Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med. Aug 26 2015;7(302):302ra136. doi:10.1126\/scitranslmed.aac9459.","DOI":"10.1126\/scitranslmed.aac9459"},{"key":"10.1016\/j.ctrv.2026.103091_b0290","doi-asserted-by":"crossref","unstructured":"Kim JW, Ko JH, Sage J. DLL3 regulates Notch signaling in small cell lung cancer. iScience. Dec 22 2022;25(12):105603. doi:10.1016\/j.isci.2022.105603.","DOI":"10.1016\/j.isci.2022.105603"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103091_b0295","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: a Comprehensive Immunohistochemical and Histopathologic Characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114248","article-title":"Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancer","volume":"159","author":"Zhang","year":"2023","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103091_b0305","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103091_b0310","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and beyond patients with DLL3-Expressing, Relapsed\/Refractory Small-Cell Lung Cancer: results from the phase II TRINITY Study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103091_b0315","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1016\/j.jtho.2021.03.012","article-title":"Rovalpituzumab Tesirine as a Maintenance Therapy after First-Line Platinum-based Chemotherapy in patients with Extensive-Stage-SCLC: results from the phase 3 MERU Study","volume":"16","author":"Johnson","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0320","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2020.04.017","article-title":"SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: phase 1 study","volume":"145","author":"Morgensztern","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2026.103091_b0325","article-title":"OA06.01 a First-In-Human phase 1 Study of SHR-4849 (IDE849), a DLL3-Directed Antibody-Drug Conjugate, in Relapsed SCLC","volume":"20(10, Supplement 1):S21","author":"Cheng","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103091_b0330","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.7150\/ijbs.105973","article-title":"Advancement Opportunities and Endeavor of innovative Targeted Therapies for Small Cell Lung Cancer","volume":"21","author":"Ouyang","year":"2025","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.ctrv.2026.103091_b0335","doi-asserted-by":"crossref","unstructured":"Len\u00e1rt S, Len\u00e1rt P, \u0160marda J, Rem\u0161\u00edk J, Sou\u010dek K, Bene\u0161 P. Trop2: Jack of All Trades, Master of None. Cancers (Basel). Nov 11 2020;12(11)doi:10.3390\/cancers12113328.","DOI":"10.3390\/cancers12113328"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103091_b0340","doi-asserted-by":"crossref","first-page":"28725","DOI":"10.18632\/oncotarget.15647","article-title":"Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes","volume":"8","author":"Inamura","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103091_b0345","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1158\/1535-7163.MCT-07-2003","article-title":"Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers","volume":"7","author":"Wang","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"26","key":"10.1016\/j.ctrv.2026.103091_b0350","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103091_b0355","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/jcp.24074","article-title":"Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the \u03b21 integrin-RACK1 axis","volume":"227","author":"Trerotola","year":"2012","journal-title":"J Cell Physiol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103091_b0360","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/onc.2012.151","article-title":"The Trop-2 signalling network in cancer growth","volume":"32","author":"Guerra","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2026.103091_b0365","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1151090","article-title":"A non-mutated TROP2 fingerprint in cancer genetics","volume":"13","author":"Guerra","year":"2023","journal-title":"Front Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103091_b0370","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2016.72.1894","article-title":"Therapy of Advanced Non-Small-Cell Lung Cancer with an SN-38-Anti-Trop-2 Drug Conjugate","volume":"35","author":"Heist","year":"2017","journal-title":"Sacituzumab Govitecan J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103091_b0375","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1080\/14712598.2023.2198087","article-title":"Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer","volume":"23","author":"Belluomini","year":"2023","journal-title":"Expert Opin Biol Ther Jul-Dec"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103091_b0380","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1158\/1078-0432.CCR-17-0933","article-title":"Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2","volume":"23","author":"Gray","year":"2017","journal-title":"Sacituzumab Govitecan Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103091_b0385","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103091_b0390","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jtho.2024.12.028","article-title":"Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in patients with Extensive-Stage SCLC: results from TROPiCS-03","volume":"20","author":"Dowlati","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2026.103091_b0395","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1158\/1078-0432.CCR-23-0536","article-title":"Targeting Replication stress and Chemotherapy Resistance with a Combination of Sacituzumab Govitecan and Berzosertib: a phase I Clinical Trial","volume":"29","author":"Abel","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.ctrv.2026.103091_b0400","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1158\/1078-0432.CCR-25-2090","article-title":"Seizure-Related Homolog Protein 6 (SEZ6): Biology and Therapeutic Target in Neuroendocrine Carcinomas","volume":"31","author":"Gezelius","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103091_b0405","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"10.1016\/j.ctrv.2026.103091_b0410","doi-asserted-by":"crossref","first-page":"5042","DOI":"10.1158\/1078-0432.CCR-24-1547","article-title":"A phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in patients with Small Cell Lung Cancer","volume":"30","author":"Morgensztern","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103091_b0415","article-title":"OA06.04 Safety and Efficacy of ABBV-706, a Seizure-related Homolog Protein 6-targeting Antibody-drug Conjugate, in R\/R SCLC","volume":"20(10, Supplement 1):S23","author":"Byers","year":"2025","journal-title":"J Thorac Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2026.103091_b0420","first-page":"36","article-title":"Significance of cell adhesion molecules, CD56\/NCAM in particular, in human tumor growth and spreading","volume":"39","author":"Zeromski","year":"2001","journal-title":"Folia Histochem Cytobiol"},{"issue":"4803","key":"10.1016\/j.ctrv.2026.103091_b0425","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1126\/science.3576199","article-title":"Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing","volume":"236","author":"Cunningham","year":"1987","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103091_b0430","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/ijc.2910440402","article-title":"Neural cell adhesion molecule (NCAM) is the antigen recognized by monoclonal antibodies of similar specificity in small-cell lung carcinoma and neuroblastoma","volume":"44","author":"Patel","year":"1989","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103091_b0435","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1208\/s12248-012-9386-x","article-title":"ADME of antibody-maytansinoid conjugates","volume":"14","author":"Erickson","year":"2012","journal-title":"AAPS J"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103091_b0440","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s10637-016-0336-9","article-title":"Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors","volume":"34","author":"Shah","year":"2016","journal-title":"Invest New Drugs"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103091_b0445","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41568-020-00322-0","article-title":"Antitumour immunity regulated by aberrant ERBB family signalling","volume":"21","author":"Kumagai","year":"2021","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103091_b0450","article-title":"Peptides for dual Targeting of ErbB1 and ErbB2: Blocking EGFR Cell Signaling Transduction Pathways for Cancer Chemotherapy","volume":"17","author":"Patnaik","year":"2024","journal-title":"Curr Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103091_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.100790","article-title":"Targeting HER3 for cancer treatment: a new horizon for an old target","volume":"8","author":"Uliano","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103091_b0460","article-title":"Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC)","volume":"43(16_suppl):3002\u20133002","author":"Huang","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103091_b0465","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ccr.2014.02.025","article-title":"ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics","volume":"25","author":"Arteaga","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2026.103091_b0470","doi-asserted-by":"crossref","unstructured":"Yao Q, Xue C, Xu Z, et al. Abstract 3146: HRA00130-C004, a novel anti-DLL3 ADC with bystander effect, high DAR and favorable safety profiles. Cancer Research. 2024;84(6_Supplement):3146-3146. doi:10.1158\/1538-7445.AM2024-3146.","DOI":"10.1158\/1538-7445.AM2024-3146"},{"key":"10.1016\/j.ctrv.2026.103091_b0475","doi-asserted-by":"crossref","unstructured":"Lin S, Zhang Y, Yao J, et al. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models. J Transl Med. Aug 14 2024;22(1):766. doi:10.1186\/s12967-024-05568-y.","DOI":"10.1186\/s12967-024-05568-y"},{"key":"10.1016\/j.ctrv.2026.103091_b0480","doi-asserted-by":"crossref","unstructured":"Lu Y, xin l, Xiao G, Puan KJ, Ling x, Yin M. Abstract 4746: PLB-001, a novel anti-dll3 ADC with topoisomerase 1 inhibitor-based linker-payload for treatment of SCLC. Cancer Research. 2025;85(8_Supplement_1):4746-4746. doi:10.1158\/1538-7445.AM2025-4746.","DOI":"10.1158\/1538-7445.AM2025-4746"},{"key":"10.1016\/j.ctrv.2026.103091_b0485","doi-asserted-by":"crossref","first-page":"144","DOI":"10.18632\/oncotarget.28559","article-title":"Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas","volume":"15","author":"Cardillo","year":"2024","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2026.103091_b0490","article-title":"Abstract 6081: Bispecific antibody drug conjugates (bsADCs) targeting DLL3 and B7-H3 demonstrated potent anti-tumor activity in preclinical models of small cell lung cancer (SCLC)","volume":"85(8_Supplement_1):6081\u20136081","author":"Zhang","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103091_b0495","article-title":"Abstract 4776: Preclinical study of bispecific antibody drug conjugates (bsADCs) targeting DLL3 and SEZ6 demonstrated potent anti-tumor activity in small cell lung cancer (SCLC) xenograft models","volume":"85(8_Supplement_1):4776\u20134776","author":"Yi","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103091_b0500","article-title":"Abstract 5087: ILB-3101, a novel B7H3-targeting ADC with Eribulin as payload, demonstrates strong tumor killing activities and favorable PK\/TOX profile in preclinical evaluation","volume":"84(6_Supplement):5087\u20135087","author":"Shang","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103091_b0505","doi-asserted-by":"crossref","unstructured":"Reveiz L, Rueda JR, Cardona AF. Chemotherapy for brain metastases from small cell lung cancer. Cochrane Database of Systematic Reviews. 2012;(6)doi:10.1002\/14651858.CD007464.pub2.","DOI":"10.1002\/14651858.CD007464.pub2"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103091_b0510","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2478\/v10019-012-0007-1","article-title":"Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting","volume":"46","author":"Lekic","year":"2012","journal-title":"Radiol Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103091_b0515","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High SCLC: results from the phase 3 TAHOE Study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103091_b0520","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.21037\/tlcr-24-964","article-title":"The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: a narrative review","volume":"13","author":"Zhou","year":"2024","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103091_b0525","doi-asserted-by":"crossref","unstructured":"Metrangolo V, Engelholm LH. Antibody-Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs. Cancers (Basel). Jan 20 2024;16(2)doi:10.3390\/cancers16020447.","DOI":"10.3390\/cancers16020447"},{"key":"10.1016\/j.ctrv.2026.103091_b0530","doi-asserted-by":"crossref","unstructured":"Hammood M, Craig AW, Leyton JV. Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development. Pharmaceuticals (Basel). Jul 15 2021;14(7)doi:10.3390\/ph14070674.","DOI":"10.3390\/ph14070674"},{"key":"10.1016\/j.ctrv.2026.103091_b0535","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7(1):93","author":"Fu","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ctrv.2026.103091_b0540","doi-asserted-by":"crossref","unstructured":"Baah S, Laws M, Rahman KM. Antibody-Drug Conjugates-A Tutorial Review. Molecules. May 15 2021;26(10)doi:10.3390\/molecules26102943.","DOI":"10.3390\/molecules26102943"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103091_b0545","first-page":"237","article-title":"Tackling solid tumour therapy with small-format drug conjugates","volume":"3","author":"Deonarain","year":"2020","journal-title":"Antib Ther"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103091_b0550","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103091_b0555","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103091_b0560","article-title":"Exploration of the antibody-drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"MAbs Jan-Dec"},{"key":"10.1016\/j.ctrv.2026.103091_b0565","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16(1):3","author":"Conilh","year":"2023","journal-title":"J Hematol Oncol Jan 17"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103091_b0570","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody-drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.ctrv.2026.103091_b0575","doi-asserted-by":"crossref","unstructured":"Sheyi R, de la Torre BG, Albericio F. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate. Pharmaceutics. Feb 11 2022;14(2)doi:10.3390\/pharmaceutics14020396.","DOI":"10.3390\/pharmaceutics14020396"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103091_b0580","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody-drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.ctrv.2026.103091_b0585","article-title":"The Chemistry Behind ADCs","volume":"14(5)doi:10.3390\/ph14050442","author":"Kostova","year":"2021","journal-title":"Pharmaceuticals (Basel) May 7"},{"key":"10.1016\/j.ctrv.2026.103091_b0590","doi-asserted-by":"crossref","unstructured":"Zhou Q. Site-Specific Antibody Conjugation for ADC and Beyond. Biomedicines. Nov 9 2017;5(4)doi:10.3390\/biomedicines5040064.","DOI":"10.3390\/biomedicines5040064"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103091_b0595","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1021\/acs.oprd.6b00067","article-title":"Processes for Constructing Homogeneous Antibody Drug Conjugates","volume":"20","author":"Jackson","year":"2016","journal-title":"Org Process Res Dev"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103091_b0600","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: a review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103091_b0605","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","article-title":"Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments","volume":"14","author":"Loganzo","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"7535","key":"10.1016\/j.ctrv.2026.103091_b0610","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nature14064","article-title":"Endophilin-A2 functions in membrane scission in clathrin-independent endocytosis","volume":"517","author":"Renard","year":"2015","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103091_b0615","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the Antibody-Drug Conjugate T-DM1 is based in a Reduction in Lysosomal Proteolytic activity","volume":"77","author":"R\u00edos-Luci","year":"2017","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103091_b0620","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","article-title":"Antibody-maytansinoid conjugates designed to bypass multidrug resistance","volume":"70","author":"Kovtun","year":"2010","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103091_b0625","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem Soc Rev"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103091_b0630","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/annonc\/mdw157","article-title":"Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib\/IIa study","volume":"27","author":"Martin","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.12.008","article-title":"Combining antibody-drug conjugates and immune-mediated cancer therapy: what to expect?","volume":"102","author":"Gerber","year":"2016","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"10.1016\/j.ctrv.2026.103091_b0640","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","article-title":"CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation are all Associated with Resistance to Brentuximab Vedotin","volume":"14","author":"Chen","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103091_b0645","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1002\/ijc.30870","article-title":"DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance","volume":"141","author":"Takegawa","year":"2017","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103091_b0650","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1515\/jtim-2024-0019","article-title":"Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows","volume":"12","author":"Tan","year":"2024","journal-title":"J Transl Int Med"},{"key":"10.1016\/j.ctrv.2026.103091_b0655","doi-asserted-by":"crossref","unstructured":"Abelman RO, Wu B, Spring LM, Ellisen LW, Bardia A. Mechanisms of Resistance to Antibody-Drug Conjugates. Cancers (Basel). Feb 17 2023;15(4)doi:10.3390\/cancers15041278.","DOI":"10.3390\/cancers15041278"},{"key":"10.1016\/j.ctrv.2026.103091_b0660","doi-asserted-by":"crossref","unstructured":"Khoury R, Saleh K, Khalife N, et al. Mechanisms of Resistance to Antibody-Drug Conjugates. Int J Mol Sci. Jun 2 2023;24(11)doi:10.3390\/ijms24119674.","DOI":"10.3390\/ijms24119674"},{"key":"10.1016\/j.ctrv.2026.103091_b0665","article-title":"Assessment of targets of antibody drug conjugates in SCLC","volume":"9(1):1","author":"Ajay","year":"2025","journal-title":"npj Precis Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103091_b0670","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in Small-Cell Lung Cancer after Platinum-based Chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103091_b0675","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","article-title":"Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study","volume":"26","author":"Paulson","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103091_b0680","doi-asserted-by":"crossref","unstructured":"Muscolino P, Omero F, Speranza D, et al. ADCs and TCE in SCLC Therapy: The Beginning of a New Era? Curr Oncol. Apr 30 2025;32(5)doi:10.3390\/curroncol32050261.","DOI":"10.3390\/curroncol32050261"},{"key":"10.1016\/j.ctrv.2026.103091_b0685","doi-asserted-by":"crossref","first-page":"S1484","DOI":"10.1016\/j.annonc.2025.08.3403","article-title":"2792TiP a phase Ib\/II study of gocatamig (MK-6070; HPN328) and ifinatamab deruxtecan for relapsed\/refractory extensive-stage small cell lung cancer (ES-SCLC)","volume":"36","author":"Bar","year":"2025","journal-title":"Ann Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T09:26:47Z","timestamp":1773998807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":137,"alternative-id":["S0305737226000058"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103091","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody\u2013Drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103091"}}